Santhera Pharmaceuticals Announces Preliminary Revenue Results for the Full Year 2016; Provides Earnings Guidance for the Full Year 2016 and Sales Guidance for the Full Year 2017
The company expects a net loss in between CHF 33 million ($33.5 million) and CHF 38 million ($38.6 million) for 2016, compared with net CHF 5.9 million ($6.1 million) gain in 2015.
The company has given guidance of CHF 21 million to CHF 23 million ($21.2 million to $23.2 million) in Raxone sales for 2017.